There are currently 603 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Effectiveness Study of OR3O™ Dual Mobility System in THA
NCT04325022
Recruiting
The purpose of this study is to assess the safety and effectiveness of the OR3O™ Dual Mobility System. The study will evaluate the outcome of the Total Hip Arthroplasty using the OR3O™ Dual Mobility System over a ten year period. Survivorship of THA will be assessed up to ten years.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
12/01/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Advanced Degeneration of the Hip Joint, Revision of the Hip Joint
Register for Updates
Clinical Performance Evaluation of T-TAS®01 HD Chip
NCT06087198
Recruiting
The study is being conducted to validate the clinical performance of the T-TAS 01 HD assay for measurement of thrombogenicity in patients with thrombocytopenia receiving a platelet transfusion.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Thrombocytopenia
Register for Updates
IC-8 Apthera IOL New Enrollment Post Approval Study
NCT06060041
Recruiting
The purpose of this study is to verify the post-market safety of the IC-8 Apthera IOL after the treatment of posterior capsular opacification (PCO), an expected complication related to IC-8 Apthera IOL implantation.
Gender:
All
Ages:
22 years and above
Trial Updated:
11/28/2023
Locations: Vance Thompson Vision - Omaha, Omaha, Nebraska
Conditions: Cataract, Presbyopia, Posterior Capsule Opacification
Register for Updates
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT05119335
Recruiting
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Hypoxia, Renal Cell Carcinoma, Hypoxia Inducible Factor (HIF), HIF2α Inhibitor, Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha), Hypoxia Inducible Factor 2α (HIF-2α), Clear Cell
Register for Updates
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279
Recruiting
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzyme... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Nebraska Medicine-Village Pointe, Omaha, Nebraska +6 locations
Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Register for Updates
The Influence of 3D Printed Prostheses on Neural Activation Patterns
NCT04110730
Recruiting
The neural basis underlying motor performance in children using a prosthesis has been severely understudied resulting in minimal empirical evidence. The use of functional near-infrared spectroscopy (fNIRS) in conjunction with customized and visually appealing 3D printed prostheses would provide the unique opportunity to quantitatively assess the influence of upper-limb prostheses in the neural activation patterns of the primary motor cortex and motor performance of children. This information wou... Read More
Gender:
All
Ages:
Between 3 years and 18 years
Trial Updated:
11/24/2023
Locations: University of Nebraska at Omaha, Omaha, Nebraska
Conditions: Amniotic Band Syndrome, Upper Extremity Deformities, Congenital
Register for Updates
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
NCT03905707
Recruiting
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
11/23/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Short Bowel Syndrome
Register for Updates
Virtual Reality Augmented Gait Adaptation in Stroke Survivors
NCT03787693
Recruiting
The major problem in stroke survivors that is being addressed in this research project is walking asymmetry, i.e., difference between the legs during walking (e.g. steps on the more affected side are longer than the other). A potential solution to this problem is using new technology like virtual reality during walking training to make stroke survivors have a better sense of their asymmetry. A second problem that we aim to address in this study is whether asymmetry is accurately felt by the stro... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
11/22/2023
Locations: University of Nebraska - Omaha, Biomechanics Research Building, Omaha, Nebraska
Conditions: Stroke
Register for Updates
The Pediatric Anesthesia Quality Improvement Project
NCT00674388
Recruiting
The Study is designed to collect information about adverse events that occur in children undergoing anesthesia in participating hospitals. Demographic information will be collected on all anesthetics. An analysis of each adverse event will be performed and entered into the database. From this information we will devise strategies to prevent these adverse events.
Gender:
All
Ages:
21 years and below
Trial Updated:
11/20/2023
Locations: Children's Hospital and Medical Center, Omaha, Nebraska
Conditions: Surgery, Anesthesia, Children
Register for Updates
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
NCT05026749
Recruiting
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.
Gender:
All
Ages:
Between 3 days and 2 years
Trial Updated:
11/20/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Respiratory Syncytial Virus Infections
Register for Updates
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
NCT05803941
Recruiting
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical tria... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
11/16/2023
Locations: Urology Cancer Center PC, Omaha, Nebraska
Conditions: Prostate Cancer
Register for Updates
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
NCT05269459
Recruiting
Double-blind placebo controlled study of Cannabidiol (CBD) for symptoms of PTSD in adults using liquid structure(TM) Formulation (Nantheia ATL5(TM)). Subjects complete 3 weeks of baseline data collection including assessments of activity and sleep. Intervention is Nantheia ATL5 or placebo. Dose is initiated at 400mg BID and maintained over 8 weeks. Standardized symptom profile measurements, clinician assessments, laboratory testing, collection of inflammatory biomarkers, and suicide screening is... Read More
Gender:
All
Ages:
Between 21 years and 65 years
Trial Updated:
11/14/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: PTSD
Register for Updates